- Home
- CRDL vs XTKG Comparison
CRDL vs XTKG Comparison
Compare CRDL & XTKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- XTKG
- Stock Information
- Founded
- CRDL 2017
- XTKG 1997
- Country
- CRDL Canada
- XTKG Singapore
- Employees
- CRDL N/A
- XTKG N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- XTKG
- Sector
- CRDL Health Care
- XTKG
- Exchange
- CRDL Nasdaq
- XTKG NYSE
- Market Cap
- CRDL 105.8M
- XTKG 16.3M
- IPO Year
- CRDL N/A
- XTKG 2019
- Fundamental
- Price
- CRDL $1.54
- XTKG $1.67
- Analyst Decision
- CRDL Strong Buy
- XTKG
- Analyst Count
- CRDL 2
- XTKG 0
- Target Price
- CRDL $9.00
- XTKG N/A
- AVG Volume (30 Days)
- CRDL 222.3K
- XTKG 111.1K
- Earning Date
- CRDL 08-11-2025
- XTKG 07-15-2025
- Dividend Yield
- CRDL N/A
- XTKG N/A
- EPS Growth
- CRDL N/A
- XTKG N/A
- EPS
- CRDL N/A
- XTKG N/A
- Revenue
- CRDL N/A
- XTKG $11,611,442.00
- Revenue This Year
- CRDL N/A
- XTKG N/A
- Revenue Next Year
- CRDL N/A
- XTKG N/A
- P/E Ratio
- CRDL N/A
- XTKG N/A
- Revenue Growth
- CRDL N/A
- XTKG N/A
- 52 Week Low
- CRDL $0.77
- XTKG $0.53
- 52 Week High
- CRDL $2.63
- XTKG $11.60
- Technical
- Relative Strength Index (RSI)
- CRDL 63.27
- XTKG 54.19
- Support Level
- CRDL $1.22
- XTKG $1.51
- Resistance Level
- CRDL $1.50
- XTKG $1.70
- Average True Range (ATR)
- CRDL 0.10
- XTKG 0.25
- MACD
- CRDL -0.00
- XTKG -0.01
- Stochastic Oscillator
- CRDL 100.00
- XTKG 44.44
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.